Update on Progress Around the World from FAST Global
Get the latest updates on FAST Global’s progress in accelerating the mission to cure Angelman Syndrome. Learn about their initiatives, collaborations, and achievements worldwide.
Toward Universal Newborn Screening for Angelman Syndrome: The Early Check Approach
Explore the Early Check program’s efforts in North Carolina to implement newborn screening for Angelman syndrome and other conditions. Learn about its goals, collaborative approach, and impact on public health policy.
The Importance of Patient Input for Coverage and Payment of New Therapies
Explore the importance of patient input in coverage and payment of new therapies with experts Sarah Pitluck and John Jarvis. Learn about pricing strategies, patient advocacy, and the role of surveys in improving access to treatments.
The Development of Rare Disease Therapeutics: Compassion and Transparency
Explore the development of rare disease therapeutics with Dr. Emil Kakkis, CEO of Ultragenyx, emphasizing compassion, transparency, and patient-centered approach in clinical trials.
Roche Angelman Syndrome Program Update – 2022
Get the latest updates on Roche’s Angelman Syndrome program, including the progress of Rugonersen, TANGELO Phase 1 drug study, PET imaging study, and the introduction of Alogabat.
Researchers Panel Discussion and Audience Q&A
Join the 2022 FAST Science Summit’s panel discussion on Angelman syndrome research and treatment. Hear from experts addressing audience questions and sh
Rapidly Evolving Opportunities for Treatments for Rare Genetic Diseases
Explore the rapidly evolving opportunities for treatments for rare genetic diseases with Dr. Wendy Chung at the 2022 FAST Science Summit. Discover the importance of early diagnosis, genomics, and precision medicine.
Pharma Panel Discussion and Audience Q&A
Join the 2022 FAST Science Summit’s Pharma Panel Discussion on Angelman Syndrome. Gain insights on treatment options, drug development, and patient advocacy from leading experts. Stay engaged and hopeful for the future.
PTC-AS Gene Therapy Program Update
Get the latest update on PTC Therapeutics’ PTC-AS gene therapy program. Discover their innovative treatments for rare disorders, recent approvals, and future plans for Angelman syndrome patients.
Novel Gene Editing Approach for Long-Term Paternal Gene Activation
Explore Yale University’s novel gene editing approach for long-term paternal gene activation in Angelman Syndrome. Discover the potential of CRISPR and STA technology in gene therapy.